Among CLL patients who harbor NOTCH1 mutations, treatment with rituximab does not result in the expected increase in PFS compared with treatment with chemotherapy regimens that do not contain rituximab, and FBXW7 serves as another biomarker of CD20 monoclonal antibody resistance[30]. This evidence concerns the gene FBXW7 and B-cell chronic lymphocytic leukemia.